☰

Adam D. Swick, Ph.D. - Publications

Affiliations: 
2013 Cellular and Molecular Biology University of Wisconsin, Madison, Madison, WI 
Area:
Immunology, Virology Biology, Chemical Engineering
Tree Info Similar researchers PubMed Report error

20 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Ayuso JM, Vitek R, Swick AD, Skala MC, Wisinski KB, Kimple RJ, Lambert PF, Beebe DJ. Effects of culture method on response to EGFR therapy in head and neck squamous cell carcinoma cells. Scientific Reports. 9: 12480. PMID 31462653 DOI: 10.1038/S41598-019-48764-3  0.317
2019 McDaniel NK, Iida M, Nickel KP, Rodems TS, Swick AD, Prabakaran PJ, Eckers-Kubatzke JC, Welke NB, Kranjac C, Schulz AE, Kimple RJ, Salgia R, Wheeler DL. Abstract A128: AXL mediates cetuximab resistance through tyrosine 821 and activation of c-Abl kinase in head and neck cancer Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A128  0.346
2018 Fisher MM, Swick AD, Nickel KP, Kimple RJ. Abstract 856: Selection of radiosensitizers based on HRAS mutation in bladder cancer Cancer Research. 78: 856-856. DOI: 10.1158/1538-7445.Am2018-856  0.344
2017 Prabakaran PJ, Javaid AM, Swick AD, Werner LR, Nickel KP, Sampene E, Hu R, Ong IM, Bruce JY, Hartig GK, Wieland A, Canon J, Harari PM, Kimple RJ. Radiosensitization of adenoid cystic carcinoma with MDM2 inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28659312 DOI: 10.1158/1078-0432.Ccr-17-0969  0.333
2017 Swick AD, Prabakaran PJ, Miller MC, Javaid AM, Fisher MM, Sampene E, Ong IM, Hu R, Iida M, Nickel KP, Bruce JY, Wheeler DL, Kimple RJ. Co-targeting mTORC and EGFR signaling as a therapeutic strategy in HNSCC. Molecular Cancer Therapeutics. PMID 28446642 DOI: 10.1200/Jco.2017.35.15_Suppl.E17509  0.385
2017 Swick AD, Stein AP, McCulloch TM, Hartig GK, Ong IM, Sampene E, Prabakaran PJ, Liu CZ, Kimple RJ. Defining the boundaries and expanding the utility of head and neck cancer patient derived xenografts. Oral Oncology. 64: 65-72. PMID 28024726 DOI: 10.1016/J.Oraloncology.2016.11.017  0.303
2017 Swick AD, Prabakaran PJ, Miller MC, Javaid AM, Fisher MM, Sampene E, Ong IM, Iida M, Wheeler DL, Nickel KP, Bruce JY, Kimple RJ. Abstract 51: Potential and challenges in co-targeting mTORC and EGFR signaling as a therapeutic strategy in HNSCC Clinical Cancer Research. 23: 51-51. DOI: 10.1158/1557-3265.Aacrahns17-51  0.393
2017 Eckers JC, Swick AD, Fowler T, Skiba J, Nickel KP, Kimple RJ. Abstract 3307: Induction of autophagy as a mechanism of therapeutic resistance in head and neck cancer Cancer Research. 77: 3307-3307. DOI: 10.1158/1538-7445.Am2017-3307  0.358
2017 Swick AD, Prabakaran PJ, Javaid A, Miller M, Fisher M, Sampene E, Ong IM, Nickel K, Kimple RJ. Abstract 149: Co-targeting mTORC and EGFR signaling as a potential therapeutic strategy in HNSCC Cancer Research. 77: 149-149. DOI: 10.1158/1538-7445.Am2017-149  0.383
2016 Fisher M, Swick AD, Nickel KP, Kimple RJ. Selection of Radiosensitizers Based on HRAS Mutation in Head and Neck Cancer. International Journal of Radiation Oncology, Biology, Physics. 96: E568-E569. PMID 27675037 DOI: 10.1016/J.Ijrobp.2016.06.2051  0.301
2016 Iida M, Bahrar H, Brand TM, Pearson HE, Coan JP, Orbuch RA, Flanigan BG, Swick AD, Prabakaran P, Lantto J, Horak ID, Kragh M, Salgia R, Kimple RJ, Wheeler DL. Targeting the HER family with Pan-HER effectively overcomes resistance to cetuximab. Molecular Cancer Therapeutics. PMID 27422810 DOI: 10.1016/S0959-8049(16)32810-6  0.32
2016 Voigt EA, Swick A, Yin J. Rapid induction and persistence of paracrine-induced cellular antiviral states arrest viral infection spread in A549 cells. Virology. 496: 59-66. PMID 27254596 DOI: 10.1016/J.Virol.2016.05.019  0.7
2016 Warrick JW, Timm A, Swick A, Yin J. Tools for Single-Cell Kinetic Analysis of Virus-Host Interactions. Plos One. 11: e0145081. PMID 26752057 DOI: 10.1371/Journal.Pone.0145081  0.684
2016 Prabakaran P, Nickel KP, Yang DT, Werner LR, Bruce JY, Wieland AM, McCulloch TM, Hartig GK, Harari PM, Swick AD, Kimple RJ. Abstract 3044: Patient-derived adenoid cystic carcinoma xenografts to study molecular target modulation of tumor radiosensitivity Cancer Research. 76: 3044-3044. DOI: 10.1158/1538-7445.Am2016-3044  0.306
2016 Swick AD, Xiaojun T, Fowler T, Nickel K, Anderson RA, Kimple RJ. Abstract 2129: Induction of autophagy as a mechanism of therapeutic resistance in head and neck cancer Cancer Research. 76: 2129-2129. DOI: 10.1158/1538-7445.Am2016-2129  0.365
2015 Pesko K, Voigt EA, Swick A, Morley VJ, Timm C, Yin J, Turner PE. Genome rearrangement affects RNA virus adaptability on prostate cancer cells. Frontiers in Genetics. 6: 121. PMID 25883601 DOI: 10.3389/Fgene.2015.00121  0.61
2015 Stein AP, Swick AD, Smith MA, Blitzer GC, Yang RZ, Saha S, Harari PM, Lambert PF, Liu CZ, Kimple RJ. Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies. Cancer Medicine. 4: 699-712. PMID 25619980 DOI: 10.1002/Cam4.387  0.337
2015 Swick AD, Gunderson D, Smith M, Blitzer G, Stein A, Nickel KP, Kimple RJ. Abstract 3603: Molecular targeting of cetuximab resistant head and neck cancer Cancer Research. 75: 3603-3603. DOI: 10.1158/1538-7445.Am2015-3603  0.372
2015 Swick A, Prabakaran J, Fisher M, Stein A, Gunderson D, Nickel K, Kimple R. Abstract A122: Pre-clinical investigation of resistance to molecular targeted therapeutics in head and neck cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-A122  0.377
2014 Swick A, Baltes A, Yin J. Visualizing infection spread: dual-color fluorescent reporting of virus-host interactions. Biotechnology and Bioengineering. 111: 1200-9. PMID 24338628 DOI: 10.1002/Bit.25170  0.648
Show low-probability matches.